Evaluation of the Safety and Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Femoral Fractures

RegeneCure

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Distal Femoral Fractures; Proximal (Subtrochanteric)Femoral Fractures

Treatments: Procedure: AMCA Bone Membrane.

Study type: Interventional

Funder types: Industry

Identifiers

NCT01687530

REGO01/12

Details and patient eligibility

About

Certain types of fractures require surgical intervention that may involve the use of bone grafts or bone graft substitutes. Many of the materials used as bone graft substitutes suffer from disadvantages such as soft tissue invasion of the fracture area, inadequate blood supply, failure to encourage the production of bone and ectopic bone formation.

A guided bone regeneration (GBR) environment may help in solving these clinical concerns. GBR has been widely used in the field of dentistry since the 1980s to provide stable placement for dental implants

The purpose of this study is to evaluate the safety, performance and initial efficacy of Regenecure's, AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.

Enrollment: 48 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age: 18 to 65 years

2. Both males and females

3. Females of child-bearing potential who have a negative urine hCG pregnancy test following informed consent and prior to surgical procedure and who are not planning to become pregnant for the duration of their part in the study

4. Femoral subtrochanteric fracture. The fracture is classified as one of the following:

   A. Closed fracture B. AO 31 A3, 33b + C1 + C2, and extending to the distal third

5. Proximal subtrochanteric femoral fracture will be treated with a cephalomedullary nail.

6. Patients must be available for follow-up for a minimum of 12 months.

Exclusion criteria

1. Trauma presentation

   • Open fractures
   • Bilateral fractures
   • Polytrauma with head injury
   • Presence of periprosthetic fractures

2. Patient Medical History

   • Previous malignancy (except basal cell carcinoma of the skin)
   • Active autoimmune disease
   • Metabolic bone disease (primary or secondary)
   • Chronic renal insufficiency (defined by a Glomerular Filtration Rate of <30 ml/min)
   • Liver function abnormality (defined by presence of ALT or AST levels more than double the upper limit)
   • Current smoker

3. Concurrent medication

   o Medications that may interfere with bone metabolism including:

4. Calcitonin for 7 days or more within the last 6 months prior to study

5. Bisphosphonates for 30 days or more within the last 12 months prior to study

6. Bone therapeutic doses of vitamin D or vitamin D metabolites for 30 days or more within the last 6 months

   • Previous or present immunosuppressive treatment
   • Previous radiotherapy or chemotherapy
   • Cumulative dose of 150mg total prednisolone or any other gluco-corticosteroid for 7 days or more within the last 6 months prior to study
   • Previous history of or current alcohol abuse
   • Previous history of or current drug addiction/abuse

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

48 participants in 1 patient group

AMCA bone membrane

Experimental group

Description:

AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.

Treatment:

Procedure: AMCA Bone Membrane.